EBS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
110.0M
-53.1%
234.3M
+50.1%
156.1M
+5.0%
148.7M
-35.7%
231.1M
Cost of Revenue
80.8M
-16.8%
97.1M
+34.9%
72.0M
-15.2%
84.9M
-1.2%
85.9M
Gross Profit
29.2M
-78.7%
137.2M
+63.1%
84.1M
+31.8%
63.8M
-56.1%
145.2M
Operating Expenses
66.5M
-74.6%
262.3M
+256.4%
73.6M
-19.7%
91.7M
+33.5%
68.7M
R&D
9.4M
+2.2%
9.2M
-12.4%
10.5M
-13.2%
12.1M
-10.4%
13.5M
SG&A
46.5M
+4.3%
44.6M
-4.3%
46.6M
-8.8%
51.1M
+31.4%
38.9M
Operating Income
-37300000
+70.2%
-125100000
-1291.4%
10.5M
+137.6%
-27900000
-136.5%
76.5M
EBITDA
-20300000
-122.5%
90.2M
+165.3%
34.0M
+335.9%
7.8M
-92.2%
99.9M
Net Income
-32700000
+81.9%
-180200000
-2750.0%
6.8M
+112.5%
-54600000
-206.6%
51.2M
EPS (Basic)
$-0.64
+81.7%
$-3.49
-2784.6%
$0.13
+112.4%
$-1.05
-209.4%
$0.96
EPS (Diluted)
$-0.64
+81.7%
$-3.49
-5085.7%
$0.07
+107.5%
$-0.93
-202.2%
$0.91
Shares (Diluted)
51.3M
-0.6%
51.6M
-8.7%
56.5M
-3.9%
58.8M
+4.1%
56.5M
Emergent Biosolutions (EBS) — Financials